Thromboembolic events following mRNA vaccines for COVID 19: a case series

Serrao, Alessandra; Agrippino, Roberta; Brescini, Mattia; Mormile, Rosaria; Chistolini, Antonio

doi:10.1007/s11239-021-02627-9

Cited by 4 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, participating OPs appeared to be up-to-date in terms of general recommendations towards SARS-CoV-2 vaccines, with the notable exception of the exemption for women previously reporting cases of deep vein thrombosis. During the first SARS-CoV-2 vaccination campaign, several claims of an increased risk of deep vein thrombosis after SARS-CoV-2 vaccination shots urged for a critical reappraisal of these vaccines in groups potentially at high-risk, including individuals with previous episodes of deep vein thrombosis, women using birth control pills or hormone replacement therapy, and pregnant women [92][93][94][95][96]. Still, most of the reported cases were actually associated with adenovirus-based formulates [92,93,97], while mRNA vaccines and subunit vaccines have shown a safer profile [92,95,96].…”

Section: Discussionmentioning

confidence: 99%

“…During the first SARS-CoV-2 vaccination campaign, several claims of an increased risk of deep vein thrombosis after SARS-CoV-2 vaccination shots urged for a critical reappraisal of these vaccines in groups potentially at high-risk, including individuals with previous episodes of deep vein thrombosis, women using birth control pills or hormone replacement therapy, and pregnant women [92][93][94][95][96]. Still, most of the reported cases were actually associated with adenovirus-based formulates [92,93,97], while mRNA vaccines and subunit vaccines have shown a safer profile [92,95,96]. Even though SARS-CoV-2 immunizations performed by means of an adenovirus carrier were discontinued during 2021, the overall attitude towards this immunization was actually associated with a quite higher RPS than that reported for mRNA formulates (19.9% ± 19.8 vs. 15.7% ± 19.4) and for SARS-CoV-2 vaccines based on the subunit technology (15.2% ± 16.1).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccine Hesitancy in Women of Childbearing Age and Occupational Physicians: Results from a Cross-Sectional Study (Italy, 2022)

Riccò

Baldassarre

Cerviere

et al. 2023

Women

View full text Add to dashboard Cite

Italian occupational physicians (OPs) are instrumental in promoting vaccination practice in occupational settings, and this study aims to characterize their attitudes, knowledge, and practices (collectively, KAP) towards immunization practice in women of childbearing age. A convenience sample of 120 OPs (50.8% males, mean age of 48.2 ± 5.9 years old) completed a structured online questionnaire (potential recipients: 2034; response rate: 5.9%) assessing their understanding of official recommendations, their general knowledge of vaccine practice, their attitudes towards vaccines, and their risk perception about vaccine-preventable infectious diseases. The sampled OPs exhibited a good understanding of official recommendations, and they were largely favorable towards vaccination of pregnant women. Knowledge status was relatively good (potential range 0 to 100%, average score 22 74.5% ± 18.2), while risk perception towards sampled disorders was heterogenous: the greatest was the one for SARS-CoV-2 (52.7% ± 32.9), followed by seasonal influenza (45.3% ± 31.6), and pertussis (37.8% 24 ± 28.2). The main predictors for promoting vaccination were higher knowledge about seasonal influenza vaccine (SIV; adjusted Odds Ratio [aOR] 102.2, 95% Confidence Interval [95%CI] 9.68–1080.26), tetanus-diphtheria-acellular pertussis vaccine (Tdap; aOR 12.34, 95%CI 2.62; 58.22) 27 and SARS-CoV-2 vaccine (aOR 14.76, 95%CI 2.74–79.69). A better attitude towards SIV was positively associated with previous vaccination of the respondent (aOR 4.90, 95%CI 1.19–20.14), while higher risk perception towards SIV was characterized as a negative predictor (aOR 0.04, 95%CI 0.01–0.35), as was working as an OP in healthcare facilities (aOR 0.03, 95%CI 0.01–0.43). Tdap was positively associated with male gender of respondents (aOR 10.22, 95%CI 2.60 to 40.24) and higher risk perception about pertussis (aOR 10.38, 95%CI 1.47 to 73.47). Overall, our data suggest that improving the understanding of OPs about the health burden of frequently encountered pathogens could be instrumental in increasing their involvement in the promotion of vaccine practice. Because of the low rate of response to our survey, our conclusions remain tentative.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Vaccine Hesitancy in Women of Childbearing Age and Occupational Physicians: Results from a Cross-Sectional Study (Italy, 2022)

Riccò

Baldassarre

Cerviere

et al. 2023

Women

View full text Add to dashboard Cite

show abstract

“…Concerns were raised also about the occurrence of venous thromboembolic events (VTE) in young women with VTE risk factors such as obesity, www.co-neurology.com hyperhomocysteinemia, estroprogestinic therapy, history of chronic venous disease, presence of prothrombin G20210A or V Leiden heterozygous [32]. A recent study has found, however, that the incidence of thromboembolic events remains higher in patients with positive SARS-CoV-2 test versus those with vaccination and SARS-CoV-2 negative [33].…”

Section: Headache and Coronavirus Disease 2019 Vaccinationmentioning

confidence: 99%

Long COVID and especially headache syndromes

Tana¹,

Giamberardino

Martelletti³

2023

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of reviewThis is an expert overview on recent literature about the complex relationship between coronavirus disease 2019 (COVID-19) and headache. Recent findingsLong COVID is a clinical syndrome characterized by the presence of persistent symptoms following the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Headache is one of the most common symptoms and is described most often as throbbing pain, associated with photo and phonofobia and worsening with physical exercise. In acute COVID-19, headache is usually described as moderate or severe, diffuse and oppressive although sometimes it has been described with a migraine-like phenotype, especially in patients with a previous history of migraine. Headache intensity during acute phase seems to be the most important predictor of duration of headache over time. Some COVID-19 cases can be associated with cerebrovascular complications, and red flags of secondary headaches (e.g. new worsening or unresponsive headache, or new onset of neurological focal signs) should be urgently investigated with imaging. Treatment goals are the reduction of number and intensity of headache crises, and the prevention of chronic forms.

show abstract

“…Among patients with prior VTE, it has been shown that there was actually a lower risk for VTE after vaccination 3 . In the background of VITT, potentially coincidental VTE events occurring after vaccination have been analyzed with increased scrutiny and even after large studies demonstrated no generalized increase in VTE risk, published case reports continue to question the safety in those with thrombophilia 6–9 with calls for definitive research in this area 10 …”

Section: Introductionmentioning

confidence: 99%

“…Among patients with prior VTE, it has been shown that there was actually a lower risk for VTE after vaccination. 3 In the background of VITT, potentially coincidental VTE events occurring after vaccination have been analyzed with increased scrutiny and even after large studies demonstrated no generalized increase in VTE risk, published case reports continue to question the safety in those with thrombophilia [6][7][8][9] with calls for definitive research in this area. 10 Patients with inherited or acquired thrombophilia remain concerned about their thrombotic risk with COVID-19 vaccination due to their unique circumstances, with some avoiding vaccination due to personal concerns or in some cases medical advice.…”

Section: Introductionmentioning

confidence: 99%

Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia

et al. 2023

View full text Add to dashboard Cite

Patients with thrombophilia remain concerned about venous thromboembolism (VTE) risk with COVID-19 vaccinations. The aim of this study was to examine VTE outcomes in patients with inherited or acquired thrombophilia who were vaccinated for COVID-19. Vaccinated patients ≥18 years between November 1, 2020 and November 1, 2021 were analyzed using electronic medical records across the Mayo Clinic enterprise. The primary outcome was imaging confirmed acute VTE occurring 90 days before and after the date of the first vaccine dose. Thrombophilia patients

show abstract

Thromboembolic events following mRNA vaccines for COVID 19: a case series

Cited by 4 publications

References 12 publications

Vaccine Hesitancy in Women of Childbearing Age and Occupational Physicians: Results from a Cross-Sectional Study (Italy, 2022)

Vaccine Hesitancy in Women of Childbearing Age and Occupational Physicians: Results from a Cross-Sectional Study (Italy, 2022)

Long COVID and especially headache syndromes

Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia

Contact Info

Product

Resources

About